Page 1991 - Williams Hematology ( PDFDrive )

1966 Part XII: Hemostasis and Thrombosis <CN>: <CT> PB

310. Skinner R, Abrahams JP, Whisstock JC, et al: The 2.6 A structure of antithrombin indicates 335. van der Logt CP, Reitsma PH, Bertina RM: Intron-exon organization of the human gene
a conformational change at the heparin binding site. J Mol Biol 266(3):601–609, 1997. coding for the lipoprotein-associated coagulation inhibitor: The factor Xa dependent
311. Li W, Johnson DJ, Esmon CT, Huntington JA: Structure of the antithrombin- inhibitor of the extrinsic pathway of coagulation. Biochemistry 30(6):1571–1577, 1991.
thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. 336. Girard TJ, Eddy R, Wesselschmidt RL, et al: Structure of the human lipoprotein-
Nat Struct Mol Biol 11(9):857–862, 2004. associated coagulation inhibitor gene. Intro/exon gene organization and localization of
312. Huber R, Carell RW: Implications of the three dimensional structure of α -antitrypsin the gene to chromosome 2. J Biol Chem 266(8):5036–5041, 1991.
1
for the structure and function of serpins. Biochemistry 28:8951–8966, 1989. 337. Tollefsen DM, Majerus DW, Blank MK: Heparin cofactor II. Purification and prop-
313. Choay J, Petitou M, Lormeau JC, et al: Structure-activity relationship in heparin: A erties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem
synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti- 257(5):2162–2169, 1982.
factor Xa activity. Biochem Biophys Res Commun 116(2):492–499, 1983. 338. Aihara K: Heparin cofactor II attenuates vascular remodeling in humans and mice. Circ
314. Bourin MC, Lindahl U: Glycosaminoglycans and the regulation of blood coagulation. J 74(8):1518–1523, 2010.
Biochem J 289(Pt 2):313–330, 1993. 339. Tollefsen DM: Vascular dermatan sulfate and heparin cofactor II. Prog Mol Biol Transl
315. Hirsh J, O’Donnell M, Eikelboom JW: Beyond unfractionated heparin and warfarin: Sci 93:351–372, 2010.
Current and future advances. Circulation 116(5):552–560, 2007. 340. Rau JC, Mitchell JW, Fortenberry YM, Church FC: Heparin cofactor II: Discov-
316. Olds RJ, Lane DA, Chowdhury V, et al: Complete nucleotide sequence of the antith- ery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost
rombin gene: Evidence for homologous recombination causing thrombophilia. 37(4):339–348, 2011.
Biochemistry 32(16):4216–4224, 1993. 341. Bertina RM, van der Linden IK, Engesser L, et al: Hereditary heparin cofactor II defi-
317. Picard V, Ersdal-Badju E, Bock SC: Partial glycosylation of antithrombin III asparag- ciency and the risk of development of thrombosis. Thromb Haemost 57(2):196–200, 1987.
ine-135 is caused by the serine in the third position of its N-glycosylation consensus 342. Corral J, Aznar J, Gonzalez-Conejero R, et al: Homozygous deficiency of heparin cofac-
sequence and is responsible for production of the beta-antithrombin III isoform with tor II: Relevance of P17 glutamate residue in serpins, relationship with conformational
enhanced heparin affinity. Biochemistry 34(26):8433–8440, 1995. diseases, and role in thrombosis. Circulation 110(10):1303–1307, 2004.
318. Turko IV, Fan B, Gettins PG: Carbohydrate isoforms of antithrombin variant N135Q 343. Broze GJJ: Protein Z-dependent regulation of coagulation. Thromb Haemost 86(1):
with different heparin affinities. FEBS Lett 335(1):9–12, 1993. 8–13, 2001.
319. Chandra T, Stackhouse R, Kidd VJ, Woo SL: Isolation and sequence characterization of 344. Heeb MJ, Cabral KM, Ruan L: Down-regulation of factor IXa in the factor Xase complex
a cDNA clone of human antithrombin III. Proc Natl Acad Sci U S A 80(7):1845–1848, by protein Z-dependent protease inhibitor. J Biol Chem 280(40):33819–33825, 2005.
1983. 345. Choi Q, Kim JE, Hyun J, et al: Contributions of procoagulants and anticoagulants to the
320. Prochownik EV, Markham AF, Orkin SH: Isolation of a cDNA clone for human antith- international normalized ratio and thrombin generation assay in patients treated with
rombin III. J Biol Chem 258(13):8389–8394, 1983. warfarin: Potential role of protein Z as a powerful determinant of coagulation assays.
321. Lane DA, Bayston T, Olds RJ, et al: Antithrombin mutation database: 2nd (1997) Thromb Res 132(1):e70–e75, 2013.
update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and 346. Bolkun L, Galar M, Piszcz J, et al: Plasma concentration of protein Z and pro-
Standardization Committee of the International Society on Thrombosis and Haemo- tein Z-dependent protease inhibitor in patients with haemophilia A. Thromb Res
stasis. Thromb Haemost 77(1):197–211, 1997. 131(3):e110–e113, 2013.
322. Broze GJ Jr, Girard TJ: Factor V, tissue factor pathway inhibitor, and east Texas bleeding 347. Huang X, Yan Y, Tu Y, et al: Structural basis for catalytic activation of protein Z-depen-
disorder. J Clin Invest 123(9):3710–3712, 2013. dent protease inhibitor (ZPI) by protein Z. Blood 120(8):1726–1733, 2012.
323. Chang JY, Monroe DM, Oliver JA, Roberts HR: TFPIbeta, a second product from the 348. Vasse M: The protein Z/protein Z-dependent protease inhibitor complex. Systemic or
mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost 81(1):45–49, local control of coagulation? Hamostaseologie 31(3):155–158, 160–154, 2011.
1999. 349. Huang X, Rezaie AR, Broze GJ Jr, Olson ST: Heparin is a major activator of the anticoagu-
324. Zhang J, Piro O, Lu L, Broze GJ Jr: Glycosyl phosphatidylinositol anchorage of tissue lant serpin, protein Z-dependent protease inhibitor. J Biol Chem 286(11):8740–8751, 2011.
factor pathway inhibitor. Circulation 108(5):623–627, 2003. 350. Sofi F, Cesari F, Abbate R, et al: A meta-analysis of potential risks of low levels of pro-
325. Piro O, Broze GJ Jr: Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost tein Z for diseases related to vascular thrombosis. Thromb Haemost 103(4):749–756,
3(12):2677–2683, 2005. 2010.
326. Girard TJ, Warren LA, Novotny WF, et al: Functional significance of the Kunitz- 351. Wei Z, Yan Y, Carrell RW, Zhou A: Crystal structure of protein Z-dependent inhibitor
type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature complex shows how protein Z functions as a cofactor in the membrane inhibition of
338(6215):518–520, 1989. factor X. Blood 114(17):3662–3667, 2009.
327. Lesnik P, Vonica A, Guerin M, et al: Anticoagulant activity of tissue factor pathway 352. Corral J, Gonzalez-Conejero R, Hernandez-Espinosa D, Vicente V: Protein Z/Z-depen-
inhibitor in human plasma is preferentially associated with dense subspecies of LDL dent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol
and HDL and with Lp(a). Arterioscler Thromb 13(7):1066–1075, 1993. 137(2):99–108, 2007.
328. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr: Purification and characterization 353. Yin ZF, Huang ZF, Cui JS, et al: Prothrombotic phenotype of protein Z deficiency. Proc
of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem Natl Acad Sci U S A 97(12):6734–6738, 2000.
264(31):18832–18837, 1989. 354. Kemkes-Matthes B, Nees M, Kuhnel G, et al: Protein Z influences the prothrombotic
329. Sandset PM, Abildgaard U, Larsen ML: Heparin induces release of extrinsic coagula- phenotype in Factor V Leiden patients. Thromb Res 106(4–5):183–185, 2002.
tion pathway inhibitor (EPI). Thromb Res 50(6):803–813, 1988. 355. Van de Water N, Tan T, Ashton F, et al: Mutations within the protein Z-dependent pro-
330. Ndonwi M, Girard TJ, Broze GJ Jr: The C-terminus of tissue factor pathway inhibi- tease inhibitor gene are associated with venous thromboembolic disease: A new form
tor alpha is required for its interaction with factors V and Va. J Thromb Haemost of thrombophilia. Br J Haematol 127(2):190–194, 2004.
10(9):1944–1946, 2012. 356. Vasse M: Protein Z, a protein seeking a pathology. Thromb Haemost 100(4):548–556,
331. Castoldi E, Simioni P, Tormene D, et al: Hereditary and acquired protein S deficiencies 2008.
are associated with low TFPI levels in plasma. J Thromb Haemost 8(2):294–300, 2010. 357. Dentali F, Gianni M, Lussana F, et al: Polymorphisms of the Z protein protease inhibitor
332. Vincent LM, Tran S, Livaja R, et al: Coagulation factor VA2440G causes east Texas and risk of venous thromboembolism: A meta-analysis. Br J Haematol 143(2):284–287,
bleeding disorder via TFPIalpha. J Clin Invest 123(9):3777–3787, 2013. 2008.
333. Duckers C, Simioni P, Spiezia L, et al: Low plasma levels of tissue factor pathway inhib- 358. Sofi F, Cesari F, Tu Y, et al: Protein Z-dependent protease inhibitor and protein Z in
itor in patients with congenital factor V deficiency. Blood 112(9):3615–3623, 2008. peripheral arterial disease patients. J Thromb Haemost 7(5):731–735, 2009.
334. Huang ZF, Broze G Jr: Consequences of tissue factor pathway inhibitor gene-disruption 359. Rezaie AR, Cooper ST, Church FC, Esmon CT: Protein C inhibitor is a potent inhibitor
in mice. Thromb Haemost 78(1):699–704, 1997. of the thrombin-thrombomodulin complex. J Biol Chem 270(43):25336–25339, 1995.

Kaushansky_chapter 114_p1949-1966.indd 1966 9/18/15 10:06 AM